Quanfu Biotech’s subsidiary Cobapsis’ AI genetic diagnosis platform appears on Japan’s national stage

InheriNext, a rare disease genetic diagnosis platform developed by Quanfu Biotech (6885 subsidiary Compass Bioinformatics), will be announced at the 70th Congress of the Japanese Society of Human Genetics on December 19 by authoritative Japanese experts in the field. The specific results of using InheriNext in actual cases, such as diagnostic efficiency and accuracy, will become one of the few start-up companies to be presented at Japan's national annual medical event.

The Annual Meeting of the Japanese Society of Human Genetics is the most representative annual event in the field of genetic medicine in Japan. It is also regarded as the largest international conference on genetics in the Eastern Hemisphere with the largest number of participants and the highest status. This annual meeting was held in Yokohama, bringing together more than a thousand clinicians from Japan and overseas. Compass was able to be published in the official agenda, showing that its technology has entered the verification level of the Japanese medical system and is gradually moving towards the introduction of actual clinical processes.

InheriNext, developed by Compass, is an AI-driven genetic diagnosis platform for rare diseases that can complete automatic analysis of whole-gene data and sort candidate variants in minutes, helping clinicians quickly focus on key clinically significant variants in large amounts of sequencing data to accelerate the clinical diagnosis of rare diseases. As clinical cases and feedback data continue to accumulate, InheriNext continues to optimize its reanalysis capabilities and becomes a core tool to support efficiency and consistency in the rare disease diagnosis process.

This presentation will be themed "Evaluation of InheriNext and Comparison of Existing Analysis Processes", focusing on the practical application of AI technology in genetic diagnosis of rare diseases, and exploring how to significantly improve diagnostic efficiency while maintaining diagnostic accuracy, a long-term core issue in clinical sites. With the popularity of next-generation gene sequencing (NGS), how to break through the limits of manual interpretation of genetic data has become an important key to whether genetic diagnosis can be scaled up.

This lecture line-up gathers three of the five national medical research centers in Japan. The lectures are delivered by NCVC experts representing the field of cardiovascular diseases and NCNP experts in the field of neuromuscular diseases. The lectures are chaired by experts from the National Center for Childhood Health Care (NCCHD), the top pediatrician. The overall lineup is very representative. In the cardiovascular disease session, the speaker will share his practical experience in introducing InheriNext as an auxiliary tool in the genetic diagnosis of cardiomyopathy-related diseases, and compare its efficiency and accuracy with expert manual interpretation. Another session will focus on the practice of genetic diagnosis of neuromuscular diseases. The speaker will share how to improve the efficiency and consistency of diagnosis by optimizing the variant annotation and data integration process in a highly professional and resource-limited research environment. He will also introduce the cooperation with Compass to verify the application results of the InheriNext scoring system in actual cases.

Compass has actively expanded into the Japanese market in recent years and currently has more than 40 university hospitals. Through this cooperation and verification with Japan's national medical research center, based on large-scale actual cases and existing diagnostic processes, we discuss how AI systems can be incorporated into the current medical system, showing that InheriNext related technologies have gradually moved from the verification stage to a practical level that can be implemented and diffused. This development is also highly consistent with the direction in which the Japanese health care system has actively promoted the institutionalization of rare disease genetic testing in recent years. Therefore, in the next stage, Compass will aim to enter the rare disease gene testing market paid for by Japan’s health insurance, and continue to develop the potential rare disease diagnostic market, which is about 90% not fully satisfied.

Chairman Lin Qun said that Quanfu Biotechnology has long-term plans for innovative new drugs and forward-looking medical technologies with international potential. InheriNext developed by Compass this time has received practical sharing and high attention from experts from multiple national research centers in Japan's highest level genetic medicine arena. It has gradually demonstrated Quanfu's business model of accelerated growth through strategic investment, allowing Quanfu to achieve specific results in its strategy of spanning the fields of precision medicine and AI medical care.